United States · FDA National Drug Code directory
Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0002-8233_03dce3f6-da85-4635-9c62-478226005b60
- Product NDC
- 0002-8233
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- Insulin lispro
- Labeler
- Eli Lilly and Company
- Marketing category
- BLA
- Marketing start / end (source format)
- 20200212
- Source listing expiry
- 20261231
Source-listed ingredients
- INSULIN LISPRO — 100 [iU]/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 5 SYRINGE in 1 CARTON (0002-8233-05) / 3 mL in 1 SYRINGE (0002-8233-01) · 0002-8233-05
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →